Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
741-760 of 847 trials

Ataxia-Telangiectasia: N-Acetyl-L-Leucine Study

We are studying whether N-Acetyl-L-Leucine can improve symptoms and quality of life for people with Ataxia-Telangiectasia. The trial will also assess the safety of this treatment.

Ataxia Telangiectasia3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Tacrolimus Monotherapy for Elderly Kidney Transplant Recipients

We are studying whether using tacrolimus alone can reduce infection risks and improve quality of life for elderly patients after a kidney transplant. This trial compares it to the standard triple medication regimen.

Kidney Transplant Complications>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineNephrology

Lung Cancer Treatment: Rilvegostomig vs. Pembrolizumab

We are studying a new drug, rilvegostomig, to see if it works better than pembrolizumab for patients with PD-L1-high metastatic non-small cell lung cancer. This trial aims to understand which treatment may improve survival and quality of life.

Lung CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Non-Small Cell Lung Cancer: M9140 Treatment Study

We are studying a new drug called M9140 for people with advanced non-small cell lung cancer. The goal is to see how well it works and how safe it is compared to existing treatments.

Non-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Pancreatic Cancer: M9140 Treatment Study

We are studying a new drug called M9140 for people with advanced pancreatic cancer to see how well it works and how safe it is. This trial aims to evaluate its effectiveness and side effects compared to standard treatments.

Metastatic Pancreatic Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Chronic Urticaria: Briquilimab Study

We are studying the long-term safety and effectiveness of briquilimab in people with chronic urticaria. This trial includes participants from earlier studies to see how well the treatment works over time.

Chronic UrticariaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyDermatology

Prostate Cancer: Atorvastatin Study

We are investigating whether atorvastatin can help delay prostate cancer progression in men receiving androgen deprivation therapy. This study aims to see if it can prevent the cancer from becoming resistant to treatment.

Metastatic Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesOncologyUrology

Moderate-to-Severe Asthma: PF-07275315 Study

We are investigating a new medication called PF-07275315 for adults with moderate-to-severe asthma. The study aims to see if it is more effective than a placebo in improving asthma control and quality of life.

Moderate-to-Severe Asthma6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementAllergologyPulmonology

Non-Small Cell Lung Cancer: Sigvotatug Vedotin with Pembrolizumab

We are studying a new treatment combining sigvotatug vedotin with pembrolizumab for patients with advanced non-small cell lung cancer that has high PD-L1 levels. The goal is to see if this combination works better than pembrolizumab alone.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Warm Autoimmune Hemolytic Anemia: Rilzabrutinib Study

We are investigating whether the oral medication rilzabrutinib can improve hemoglobin levels and reduce symptoms in adults with warm autoimmune hemolytic anemia. This study will also assess its safety compared to a placebo.

Autoimmune Hemolytic Anemia1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesHematologyInternal Medicine

Moderate Atopic Dermatitis: Ruxolitinib Cream for Kids

We are studying a new cream for children and adolescents aged 6 to under 18 with moderate atopic dermatitis who haven't had success with other treatments. The trial will assess how well it works and its safety.

Atopic Dermatitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Heart Attack Treatment: Evolocumab vs. Standard Care

We are studying whether the medication evolocumab can better prevent heart-related problems compared to standard treatments for patients who have recently had a heart attack. This trial focuses on improving cholesterol control and reducing hospitalizations.

Heart Attack>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Pancreatic Cancer: Napabucasin with Chemotherapy

We are studying how well Napabucasin works with chemotherapy for patients with metastatic pancreatic cancer after previous treatments have failed. The goal is to see if this combination improves survival and quality of life compared to standard care.

Metastatic Pancreatic CancerEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Plozasiran for Severe Hypertriglyceridemia: SHASTA-5 Study

We are studying whether plozasiran can help adults with severe hypertriglyceridemia reduce their triglyceride levels and lower the risk of acute pancreatitis. The trial also looks at the treatment's safety and how it affects patients' overall health.

High Triglycerides>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterology

Hereditary Angioedema: BW-20805 Study

We are investigating the effects and safety of BW-20805 in adults with hereditary angioedema. The study aims to see if it can help reduce the number of HAE attacks.

Hereditary Angioedema1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyInternal Medicine

Ketamine Therapy for Obsessive-Compulsive Disorder

We are studying whether ketamine can effectively reduce symptoms of obsessive-compulsive disorder. This trial will help us understand its impact on mental function during stressful situations.

Obsessive Compulsive Disorder (OCD)≤3 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePsychiatry

Metastatic Non-Small-Cell Lung Cancer: Tedopi Combinations

We are studying the effects of Tedopi combined with either docetaxel or nivolumab in patients with advanced lung cancer who have not responded to previous treatments. This trial aims to see if these combinations can improve survival rates and overall health.

Metastatic Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Lung Health: Avalyn Inhaled Antifibrotic Study

We are studying the long-term safety and effects of Avalyn's inhaled antifibrotic medications on lung function in patients who have previously participated in related trials.

Pulmonary FibrosisEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePulmonology

Crohn’s Disease: Tulisokibart Treatment Study

We are testing a new medication, tulisokibart, for people with moderately to severely active Crohn’s disease. The goal is to see if it helps achieve remission and improve symptoms compared to a placebo.

Crohn's Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Uncontrolled Asthma: GSK5784283 Treatment Study

We are testing a new antibody treatment for adults with uncontrolled asthma to see if it helps improve lung function and asthma control compared to a placebo.

Asthma1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPulmonology